* ERYTECH PHARMA *
2004 - Rhône-Alpes
Lyon
www.erytech.com Delivery, Drugs
Key words: Encapsulation, Red blood cells, Cancer, Cleav'Ery, Oxygen'Ery, Deliv'Ery, Vaccin'Ery, Graspa
Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients
Clients: Prescribers
contact@erytech.com
Age: 7 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Goineau (Pierre-Olivier) [co-founder, born 1967, ex-KPMG]
Oper.Dir.:
Sc.Dir.-CSO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed]
Med.Dir.: Liens (David) [M.D., ex-Merck (KgaA)
Fin.Dir.-CFO: Dujardin (Philippe) [Ms. finance, ex-Atari, Suez-Lyonnaise des Eaux]
BusDev: Bouvier (Maud) [Sup de Co (Grenoble)]
Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys | Turnover (M€) : n.a.
Total funding (M€) : 13.0
Last funding (M€) : 12.0
Focus : Cancers
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .06 | Partnering distribution agreement with Teva on encapsulated drugs in red cells | MKTG | [6 years] |
| 2010 .10 | Partnering R&D agreement with Genzyme on novel therapeutic enzyme formulation | R&D | [5 years] |
| 2010 .01 | Registration : orphan Drug designation by FDA for GRASPA | MKTG | [5 years] |
| 2009 .01 | Partnering R&D agreement with American Red Cross to produce Graspa for clinical trials in USA | R&D | [4 years] |
| 2008 .10 | Clinical trial (phase II) for new vaccine concept against cancer, based on red blood cells, Vaccin'ERY (completed, positive) | CLIN | [3 years] |
| 2008 .05 | Clinical trial (phase II) for Graspa (orphan drug) in leukemia (completed) | CLIN | [3 years] |
| 2006 .11 | 1st round-financing : 12.0 M€, by AXA P.E., Auriga Partners, AGF P.E., Capdecisif | RFINA | [2 years] |
| 2006 .06 | Registration : orphan Drug designation by EMEA for GRASPA | MKTG | [1 year] |
| 2005 .11 | Clinical trial (phase II) for lead compound in leukemia (beginning) | CLIN | [1 year] |
| 2005 .10 | Seed financing : 0.75 M€, by Amorçage Rhône Alpes (+ 0.45 M€ from contest by French Ministry of R&D) | SFIN | [0 year] |
| 2004 .11 | Company founded by Yann Godfrin and Pierre-Olivier Goineau | ORGF | [0 year] | Actualisation / Updating: 23-Sep-2011 |
|
